NCT02567643撤回不适用
Stereotactic Radiosurgery for Multiple (5+) CNS Metastases
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Overall survival
研究概览
简要总结
This study is designed to determine outcome for patients with 5 or more central nervous system (CNS) metastatic lesions treated with stereotactic radiosurgery (SRS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •CNS metastatic disease with 5 to 25 CNS mets that require treatment (note that previous SRS, WBRT, and resection for previous CNS mets is allowed. At time of protocol treatment, patient must have 5 or more new or progressing CNS mets that require treatment, this includes new lesions not before seen or progression of previous lesions.). While definition of new lesions is fairly straightforward, the definition of progression of old lesion is at the discretion of the treating team but it is recommended that progression be defined by a multidisciplinary team (radiation oncologist, neurosurgeon, neuro-radiologist). Note that treatment of tumor bed does not count as treatment of an active lesion.
- •For example,
- •Patient with 10 lesions in 2010 who had whole brain radiation and now has 2 new lesions and progression of 3 previously noted lesions would be eligible
- •Patient with 31 lesions in 2010 who had whole brain radiation and now has 26 stable lesions and progression of 5 lesions is eligible. Although the patient has more than 25 lesions the majority are stable and do not require treatment.
- •Patient with 6 brain lesions has surgical resection of one lesion is eligible. Patient will require treatment for 5 lesions. Patient can also have treatment of surgical tumor bed but this does not count towards 5 lesions required for eligibility.
- •All lesions < 4 cm in greatest dimension
- •Able to have an MRI with contrast
- •MRI within 6 weeks (MRI for eligibility can be done without contrast but planning MRI for radiosurgery will have contrast).
- •Patients of child-bearing age must agree to contraception until radiosurgery has been completed.
- •Patients able to undergo radiosurgery. Gamma knife radiosurgery is preferred for this protocol but cyberknife can also be used at the discretion of treating physicians.
- •Karnofsky Performance Scale (KPS) 50 or better
- •Eligible primaries:
- •Lung (NSCLC)
- •Lung (SCLC) that have had previous whole brain radiation
- •Head and Neck
排除标准
- •Less than 5 CNS lesions (can have had previously treated lesions by either surgery or SRS, but at time of protocol SRS must have 5 or more untreated lesions).
- •More than 25 CNS lesions that require treatment (note that the patient can have had previous metastatic lesions, but at the time of enrollment cannot have more than 25 new lesions).
- •For example:
- •Patient with 12 brain lesions has whole brain radiation in 2010, on follow-up has progression of 3 lesions is not eligible since less than 5 lesions require treatment.
- •Patient with 5 brain lesions has surgical resection of one lesions, patient is not eligible since has less than 5 lesions that require treatment.
- •Ineligible primaries Lymphoma Lung (SCLC) that have not had previous whole brain radiation Primary CNS tumors Leptomeningeal disease in CNS
- •Must not have any chemotherapy or targeted therapy within 24 hours prior to SRS
- •Patients unable to have an MRI (secondary for example to metal hardware)
- •Patients unable to have MRI contrast (secondary for example to poor renal function).
- •CNS lesion > 4 cm in any dimension
- •KPS 40 or less
- •Serious or other life threatening illness as determined by the treating physician
结局指标
主要结局
Overall survival
时间窗: 6 months
Distant CNS free survival (new lesions in CNS)
时间窗: 6 months
次要结局
- Adverse Events for Safety and Tolerability of treatment(6 months)
- Quality of life (as determined by FACT-Br)(6 months)
- Local control (For CNS, local control refers to treated lesions)(6 months)
- Timing and need for salvage therapy (whole brain radiation or repeat whole brain radiation)(6 months)
- Median dose to whole brain with SRS(6 months)
- Neurocognitive testing (Montreal Cognitive Assessment)(6 months)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain MetastasisMetastatic Lung Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8NCT04516070M.D. Anderson Cancer Center55
终止
不适用
A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed With Stereotactic Radiosurgery (SRS)Brain MetastasesNCT01821443University of California, San Francisco10
招募中
2 期
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-activeBrain MetastasesNCT06649058M.D. Anderson Cancer Center316
已完成
3 期
Surgery Versus Stereotactic Radiosurgery in the Treatment of Single Brain Metastasis: A Randomized TrialBrain CancerNCT00460395M.D. Anderson Cancer Center64
终止
不适用
Whole Brain Radiotherapy (WBRT) Versus Stereotactic Radiosurgery (SRS) for 4 Upto 10 Brain MetastasesNeoplasm MetastasisNCT02353000Maastricht Radiation Oncology31